Mr. Bruce Clark reports

NIRVANA LIFE SCIENCES INC. ANNOUNCES RECEIPT OF FIRST NORTH AMERICAN PRODUCTION OF SOSA, A PATENTED, WHO APPROVED, HERBAL TREATMENT FOR OPIATE ADDICTION

Nirvana Life Sciences Inc. has received its first shipment of SOSA, a leading addiction-focused herbal treatment.

SOSA is a patented, WHO-approved (World Health Organization) herbal treatment for opiate addiction that has been administered to more than 30 million patients in Asia. SOSA is registered with the health authorities in China, Indonesia, Thailand, Vietnam and Cambodia and has been used to safely and effectively treat opiate addictions in these countries for over 20 years. A report from the WHO concluded that SOSA can be used safely and effectively for heroin and other opiate addiction treatment, detoxification and acute heroin withdrawal symptoms. In addition, the side effects are minimal and tolerable.

SOSA has been proven to be effective at breaking the cycle of addiction to opioids and other opiate-based addictive drugs.

The U.S. Council of Economic Advisors estimates the cost of the opioid crisis to the U.S. economy at more than $500-billion annually; this equates to almost 4 per cent of GDP (gross domestic product). In 2021, more than 75,000 Americans died of drug overdose, with around two-thirds of those deaths linked to opioids. The impact can be measured financially, with massive health care and insurance costs as well as the significant costs of law enforcement. It has been estimated that it will require a large investment, as much as $100-billion, to fully address the crisis.

This first shipment will be used for analysis and preclinical trials. The company expects to commence selected trials and finalize distribution contracts in the coming weeks.

Nirvana chief executive officer Bruce Clark stated: "We believe that the SOSA product can be a game changer in the effort to help those afflicted with opiates addiction-related disorders. The Nirvana project was formed with the belief that innovation can make a difference to people affected by this crisis."

About Nirvana Life Sciences Inc.

Nirvana Life Sciences has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that mitigate the symptoms of chronic pain and support patients who battle with addiction. Nirvana believes that pairing naturally sourced psychedelics with modern medicine holds the promise of delivering non-addictive therapeutic solutions. Backed by a team of global leading researchers, Nirvana will develop life-changing therapies for those suffering from pain and addiction and consequently alleviate the fiscally strained medical system.

We seek Safe Harbor.